Investigating a signaling network that causes heart cell death.
A K63-Ubiquitination Dependent Necroptosis Signaling Network in the Heart
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11001102
This study is looking at a special process that causes heart cells to die when the heart is injured, and it's trying to find ways to stop that from happening, which could help people with heart problems feel better and stay healthier.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11001102 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding a specific type of programmed cell death called necroptosis, which is significant in heart conditions like ischemic injury and heart failure. The researchers are exploring how a unique signaling network involving K63-linked polyubiquitination affects heart cells during injury. By studying the roles of certain proteins, they aim to identify ways to prevent heart cell death and improve heart health. This could lead to new treatments that protect the heart from damage.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing cardiac ischemia or related heart conditions.
Not a fit: Patients with non-cardiac conditions or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect heart cells from death, potentially improving outcomes for patients with heart disease.
How similar studies have performed: Other research has shown promising results in understanding programmed cell death in the heart, suggesting that this approach could lead to significant advancements.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, QINGHANG — UNIVERSITY OF WASHINGTON
- Study coordinator: LIU, QINGHANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.